DX3-213B
Tocris Bioscience, part of Bio-Techne | Catalog # 8070
Potent NDUFS7 antagonist
Key Product Details
Description
Potent NDUFS7 antagonist
Product Description
DX3-213B is a potent oxidative phosphorylation (OXPHOS) complex I (also known as NDUFS7) antagonist (IC50 = 3.6 nM). DX3-213B impairs ATP generation (IC50 = 11 nM) and inhibits the proliferation of MIA PaCa-2 cells (IC50 = 9 nM) in galactose-containing media. In vivo, DX3-213B significantly delays tumor growth in a syngeneic mouse model of pancreatic cancer. DX3-213B is orally bioavailable.Licensing Information
Sold under license from the University of MichiganProduct Specifications
Molecular Weight
478.57
Formula
C20H28F2N2O5S2
Storage
Store at -20°C
Purity
≥97% (HPLC)
Chemical Name
(4,4-Difluoro-1-piperidinyl)[(3R)-1-[[4-[(1-methylethyl)sulfonyl]phenyl]sulfonyl]-3-piperidinyl]methanone
CAS Number
2749555-66-4
PubChem ID
162365370
InChI Key
HLSJMSNPBRGRGL-MRXNPFEDSA-N
SMILES
O=S(N1C[C@H](C(N2CCC(CC2)(F)F)=O)CCC1)(C3=CC=C(S(C(C)C)(=O)=O)C=C3)=O
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 23.93 | 50 |
Preparing Stock Solutions
for DX3-213B
The following data is based on the product molecular weight 478.57
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 4.18 mL | 20.90 mL | 41.79 mL |
| 2.5 mM | 0.84 mL | 4.18 mL | 8.36 mL |
| 5 mM | 0.42 mL | 2.09 mL | 4.18 mL |
| 25 mM | 0.08 mL | 0.42 mL | 0.84 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Xue Multiparameter optimization of oxidative phosphorylation inhibitors for the treatment of pancreatic cancer. J.Med.Chem. 2022 PMID: 35167303
- Xu First-in-class NADH/Ubiquinone oxidoreductase core subunit S7 (NDUFS7) antagonist for the treatment of pancreatic cancer. ACS Pharmacol.Transl.Sci. 2023 PMID: 37588763
Product Specific Notices for DX3-213B
For research use only
Loading...
Loading...